Comparative Analysis of Cytokine Expression Profiles in Prostate Cancer Patients

This study aimed to identify the cytokine expression profile in prostate cancer (PCa) patients compared to healthy individuals. Plasma samples from 75 PCa patients and 14 healthy controls were analyzed using Multiplex ELISA (Luminex) to measure the expression levels of 12 cytokines: IL-4, IL-5, IL-6...

Full description

Saved in:
Bibliographic Details
Published inBiology (Basel, Switzerland) Vol. 14; no. 5; p. 505
Main Authors Coelho, Karoline Brito Caetano Andrade, Wosniaki, Denise Kusma, Pereira, Jonatas Luiz, Luz, Murilo, Albrecht, Letusa, Nardin, Jeanine Marie, Aoki, Mateus Nobrega, Reis, Leonardo O., dos Reis, Rodolfo Borges, Zanette, Dalila Lucíola
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 06.05.2025
MDPI
Subjects
Online AccessGet full text
ISSN2079-7737
2079-7737
DOI10.3390/biology14050505

Cover

More Information
Summary:This study aimed to identify the cytokine expression profile in prostate cancer (PCa) patients compared to healthy individuals. Plasma samples from 75 PCa patients and 14 healthy controls were analyzed using Multiplex ELISA (Luminex) to measure the expression levels of 12 cytokines: IL-4, IL-5, IL-6, IL-10, IL-1β, IL-17A, IL-12p70, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, TNF-α, and IFN-γ. Differences in cytokine expression levels were analyzed using the Mann–Whitney test, Wilcoxon’s rank-sum test, Spearman’s rank correlation, and K-means Clustering unsupervised machine learning to validate cytokine expression patterns. In PCa patients, MIP-1α/CCL3, MIP-1β/CCL4, IFN-γ, and interleukins exhibited significantly higher expression levels; conversely, TNF-α and MCP-1/CCL2 both had decreased expression compared to healthy individuals. The clustering analysis confirmed that PCa patients exclusively exhibit the highest associations with MIP-1α/CCL3, IFN- γ, IL-12p70, IL-4, and IL-5. Furthermore, specific correlations between IL-4 and MIP-1 beta, IL-4 and IFN-gamma, IL-5 and IL-12p70, and IL-5 and IFN-gamma in PCa patients did not occur in healthy individuals. Such results will guide forthcoming in vitro and in vivo human prostate cancer-drug treatment models, paving the way for exploration of future drug targets and candidates with potential to predict FDA-approved prostate cancer treatment responses by targeting cytokine levels and the oncogenesis pathways.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2079-7737
2079-7737
DOI:10.3390/biology14050505